Primary Ovarian Leiomyosarcoma Is a Very Rare Entity: A Narrative Review of the Literature
Cancers · 28.05.2023 · 15 (11) · 2953
DOI: 10.3390/cancers15112953 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 28.05.2023. Verfasst von Vincenzo Dario Mandato und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Obstetrics and Oncological Gynecology, Azienda USL-IRCCS di, 42122 Reggio Emilia, Italy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health—Programma Ricerca Corrente.
Abstract (Originalsprache)
Background
Primary ovarian leiomyosarcoma is a very rare malignancy characterized by unclear management and poor survival. We reviewed all the cases of primary ovarian leiomyosarcoma to identify prognostic factors and the best treatment.
Methods
We collected and analyzed the articles published in the English literature regarding primary ovarian leiomyosarcoma from January 1951 to September 2022, using PubMed research. Clinical and pathological characteristics, different treatments and outcomes were analyzed.
Results
113 cases of primary ovarian leiomyosarcoma were included. Most patients received surgical resection, associated with lymphadenectomy in 12.5% of cases. About 40% of patients received chemotherapy. Follow-up information was available for 100/113 (88.5%) patients. Stage and mitotic count were confirmed to affect survival, and lymphadenectomy and chemotherapy were associated with a better survival rate. A total of 43.4% of patients relapsed, and their mean disease-free survival was 12.5 months.
Conclusions
Primary ovarian leiomyosarcomas are more common in women in their 50s (mean age 53 years). Most of them are at an early stage at presentation. Advanced stage and mitotic count showed a detrimental effect on survival. Surgical excision associated with lymphadenectomy and chemotherapy are associated with increased survival. An international registry could help collect clear and reliable data to standardize the diagnosis and treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Obstetrics and Oncological Gynecology, Azienda USL-IRCCS di, 42122 Reggio Emilia, Italy.
- Laboratory of Translational Research, Azienda USL-IRCCS di, 42122 Reggio Emilia, Italy.
- Unit of Pathology, Azienda USL-IRCCS di, 42122 Reggio Emilia, Italy.
- Unit of Obstetrics and Gynecology, Santa Maria delle Grazie Hospital, 80100 Naples, Italy.
ORCID-Profile: Vincenzo Dario Mandato, Andrea Palicelli
Förderung
- Italian Ministry of Health—Programma Ricerca Corrente
Zitieren
APA
Mandato, V. D., Torricelli, F., Mastrofilippo, V., Palicelli, A., Costagliola, L., & Aguzzoli, L. (2023). Primary Ovarian Leiomyosarcoma Is a Very Rare Entity: A Narrative Review of the Literature. Cancers, 15(11), 2953. https://doi.org/10.3390/cancers15112953
Vancouver
Mandato VD, Torricelli F, Mastrofilippo V, Palicelli A, Costagliola L, Aguzzoli L. Primary Ovarian Leiomyosarcoma Is a Very Rare Entity: A Narrative Review of the Literature. Cancers. 2023;15(11):2953. doi:10.3390/cancers15112953
BibTeX
@article{Mandato2023,
author = {Mandato, Vincenzo Dario and Torricelli, Federica and Mastrofilippo, Valentina and Palicelli, Andrea and Costagliola, Luigi and Aguzzoli, Lorenzo},
title = {Primary Ovarian Leiomyosarcoma Is a Very Rare Entity: A Narrative Review of the Literature},
journal = {Cancers},
year = {2023},
volume = {15},
number = {11},
pages = {2953},
doi = {10.3390/cancers15112953}
}
EUVIMED